← Sarepta Therapeutics, Inc. (SRPT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Sarepta Therapeutics, Inc. (SRPT)
Pharmaceutical Preparations · market cap $2.0B · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-31 (est.)
Phase 3
Pipeline
9
programs
Upcoming events
4
next 90d+
Dossier
Ready
cached
Sarepta Therapeutics (SRPT) is a Cambridge, MA-based rare disease drugmaker focused primarily on Duchenne Muscular Dystrophy (DMD), with four approved drugs as of 2023 and a multi-asset pipeline spanning Phase 2 and Phase 3. The stock trades at ~$17.61 with a $1.86B market cap — deeply depressed relative to its $2.2B 2025 revenue base — amid a 27% short float and only ~11 months of runway on current cash. The pivotal near-term binary is a Phase 3 Eteplirsen readout estimated October 2026, rated 9/10 importance, followed by a regulatory event in February 2027.
The catalyst path
- 2026-10-31 (est.)Phase 3 · Eteplirsenimp 9/10
- 2026-11-02 (est.)Earningsimp 5/10
- 2026-12-31 (est.)Phase 2 · ARO-DM1 Intravenous (IV) Infusionimp 7/10
- 2027-02-28Regulatoryimp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| RESTEN-MP | Phase 2 | Coronary Artery Disease |
| SRP-4045 | Phase 3 | Duchenne Muscular Dystrophy |
| Eteplirsen | Phase 3 | Duchenne Muscular Dystrophy |
| SRP-9003 | Phase 3 | Limb-girdle Muscular Dystrophy |
| AVI-4658 (Eteplirsen) | Phase 2 | Duchenne Muscular Dystrophy (DMD) |
| AVI-4658 for Injection | Phase 2 | Duchenne Muscular Dystrophy |
| SRP-4053 | Phase 2 | Duchenne Muscular Dystrophy |
| AVI-4658 (PMO) | Phase 2 | Duchenne Muscular Dystrophy |
| Amondys 45 | Phase 2 | Duchenne Muscular Dystrophy |
Price & technical context
3-month
-8.9%
6-month
-20.6%
12-month
-9.1%
52-wk range
$14.86–$24.45
vs 50-day MA
-6.7%
vs 200-day MA
-8.2%
Realized vol
82.4%
Max drawdown
-91.4%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SRPT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.